| Paris | |
| 176 | |
| Develops innovative drugs for metabolic diseases, currently focused on type 2 diabetes. | |
| Our lead compound, Imeglimin, which targets mitochondrial dysfunction, has completed Phase 2 clinical development for type 2 diabetes in the EU and US, and has entered Phase 2b clinical development in Japan. This product has demonstrated a robust efficacy and an excellent safety profile in 7 phase 2 trials in more than 600 patients, as a monotherapy treatment (primary and secondary endpoints met in a Phase 2b dose-ranging trial), as well as in combination with the 2 most important drugs prescribed to T2D patients, metformin and sitagliptin. | |
| KUHN Thomas | |
| www.poxel.com | |
| POXEL:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 10 fois.